Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorHenan Cancer Hospital
About this trial
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosed as lymphoma (according to WHO 2017 classification criteria)
Life expectancy no less than 3 months
Agreeing to sign the written informed consents
Disqualifiers
Other malignant tumor history or active malignant tumor need be treated
Researchers determine unsuited to participate in this trial
Trial population
Including demographic characteristics / clinical characteristics / pathological characteristics / treatment and efficacy evaluations.
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Incidence of driver gene abnormalities
the incidence of driver gene abnormalities by fixed gene testing technology
Time frame
from the day of the first patient was included to the date of the end of this trial, assessed up to 36 monthsSecondary outcomes
1
objective response rate
the total proportion of patients with complete response (CR) and partial response (PR)
Time frame
from the date of the first patient was included to the date of the end of this trial, assessed up to 36 months2
5-year overall survival
from the date of first patient was included to the date of death by any cause
Time frame
from the date of the first patient was included to the date of the end of this trial, assessed up to 5 years3
Clinicopathological Characteristics
study data on clinicopathological characteristics related to incidence of driver gene abnormalities
Time frame
from the date of the first patient was included to the date of the end of this trial, assessed up to 36 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov